Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blinded, Phase 3, Multicenter, Investigator-initiated Trial for Entecavir for Prophylaxis of Hepatitis B Virus (HBV) Reactivation in HBV Surface Antigen or Anti-HBc Positive Patients Undergoing Anti-TNFα Treatment

NCT01694264 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT01694264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01694264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blinded, Phase 3, Multicenter, Investigator-initiated Trial for Entecavir for Prophylaxis of Hepatitis B Virus (HBV) Reactivation in HBV Surface Antigen or Anti-HBc Positive Patients Undergoing Anti-TNFα Treatment
Lead sponsor
Seoul National University Hospital
Phase
Phase 3
Overall status
Terminated
Start date
September 1, 2012
Completion date
December 31, 2015
Enrollment
43 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, chronic hepatitis b, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis